These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
6. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Saunders P; Tsipouri V; Keir GJ; Ashby D; Flather MD; Parfrey H; Babalis D; Renzoni EA; Denton CP; Wells AU; Maher TM Trials; 2017 Jun; 18(1):275. PubMed ID: 28619061 [TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
8. Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases. Salonen J; Purokivi M; Bloigu R; Kaarteenaho R BMJ Open Respir Res; 2020 Apr; 7(1):. PubMed ID: 32265195 [TBL] [Abstract][Full Text] [Related]
9. The Relevance of REMAP-ILD for Ibero-American Countries: A Randomized Embedded Multifactorial Adaptive Platform (REMAP) Trial in the Field of Interstitial Lung Diseases (ILDs). Kawano-Dourado L; Molina-Molina M; Sellares J; Enghelmayer JI Arch Bronconeumol; 2024 Aug; 60(8):463-465. PubMed ID: 38816284 [No Abstract] [Full Text] [Related]
10. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Saketkoo LA; Mittoo S; Huscher D; Khanna D; Dellaripa PF; Distler O; Flaherty KR; Frankel S; Oddis CV; Denton CP; Fischer A; Kowal-Bielecka OM; LeSage D; Merkel PA; Phillips K; Pittrow D; Swigris J; Antoniou K; Baughman RP; Castelino FV; Christmann RB; Christopher-Stine L; Collard HR; Cottin V; Danoff S; Highland KB; Hummers L; Shah AA; Kim DS; Lynch DA; Miller FW; Proudman SM; Richeldi L; Ryu JH; Sandorfi N; Sarver C; Wells AU; Strand V; Matteson EL; Brown KK; Seibold JR; Thorax; 2014 May; 69(5):428-36. PubMed ID: 24368713 [TBL] [Abstract][Full Text] [Related]
11. Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. Behr J; Neuser P; Prasse A; Kreuter M; Rabe K; Schade-Brittinger C; Wagner J; Günther A BMC Pulm Med; 2017 Sep; 17(1):122. PubMed ID: 28877715 [TBL] [Abstract][Full Text] [Related]
12. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M; Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830 [TBL] [Abstract][Full Text] [Related]
13. Cell-Based Therapy for Fibrosing Interstitial Lung Diseases, Current Status, and Potential Applications of iPSC-Derived Cells. Nakamura Y; Niho S; Shimizu Y Cells; 2024 May; 13(11):. PubMed ID: 38891026 [TBL] [Abstract][Full Text] [Related]
14. Systemic corticosteroids in fibrotic lung disease: a systematic review and meta-analysis. Pitre T; Kawano-Dourado L; Kachkovski GV; Leung D; Leung G; Desai K; Zhai C; Adams W; Funke-Chambour M; Kreuter M; Stewart I; Ryerson CJ; Jenkins G; Zeraatkar D; BMJ Open Respir Res; 2023 Dec; 10(1):. PubMed ID: 38160015 [TBL] [Abstract][Full Text] [Related]
15. Investigating significant health trends in progressive fibrosing interstitial lung disease (INSIGHTS-ILD): rationale, aims and design of a nationwide prospective registry. Behr J; Bonella F; Günther A; Koschel D; Prasse A; Pittrow D; Klotsche J; Kreuter M; BMC Pulm Med; 2023 Feb; 23(1):64. PubMed ID: 36774483 [TBL] [Abstract][Full Text] [Related]
16. Immune mechanisms in fibrotic interstitial lung disease. Kamiya M; Carter H; Espindola MS; Doyle TJ; Lee JS; Merriam LT; Zhang F; Kawano-Dourado L; Sparks JA; Hogaboam CM; Moore BB; Oldham WM; Kim EY Cell; 2024 Jul; 187(14):3506-3530. PubMed ID: 38996486 [TBL] [Abstract][Full Text] [Related]
17. Neighborhood-Level Disadvantage Impacts on Patients with Fibrotic Interstitial Lung Disease. Goobie GC; Ryerson CJ; Johannson KA; Schikowski E; Zou RH; Khalil N; Marcoux V; Assayag D; Manganas H; Fisher JH; Kolb MRJ; Gibson KF; Kass DJ; Zhang Y; Lindell KO; Nouraie SM Am J Respir Crit Care Med; 2022 Feb; 205(4):459-467. PubMed ID: 34818133 [No Abstract] [Full Text] [Related]
18. Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: a population-based study. Cao M; Sheng J; Qiu X; Wang D; Wang D; Wang Y; Xiao Y; Cai H BMC Pulm Med; 2019 Nov; 19(1):215. PubMed ID: 31727051 [TBL] [Abstract][Full Text] [Related]
19. A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival. Hyldgaard C Dan Med J; 2015 Apr; 62(4):B5069. PubMed ID: 25872544 [TBL] [Abstract][Full Text] [Related]
20. Diagnosis and Management of Fibrotic Interstitial Lung Diseases. Collins BF; Luppi F Clin Chest Med; 2021 Jun; 42(2):321-335. PubMed ID: 34024407 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]